VML Health, a marketing and communications company, has identified the concept's emergence as a trend affecting how ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion.  | In a flurry of activity, biopharma ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

For more than a year, the biopharma industry has had to swiftly react to various tariff threats from the Trump administration. | The president has rolled out a 100% tariff rate on patented ...

Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...

With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...

With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...

The brief reign of Novo Nordisk’s Wegovy pill as the lone oral GLP-1 approved for obesity has ended as Eli Lilly’s ...

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

The U.K. can officially declare itself free of tariffs on drug exports to the U.S. after its government signed off on the ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...